CRM-197 protein is a highly valued non-toxic mutant of diphtheria toxin widely used as a carrier protein in vaccine development, especially for polysaccharide- and hapten-conjugate vaccines. It is one of the most established carrier proteins in the global biopharmaceutical and vaccine research market because it helps improve the immunogenicity of weak antigens and supports efficient antigen presentation. This makes CRM-197 protein particularly suitable for conjugate vaccine platforms where a carrier backbone is required to trigger a stronger immune response. Beyond vaccine development, CRM-197 protein is also used in cancer therapy research and related immunology applications, where a reliable and well-characterized carrier protein is needed. The product is offered in research grade and GMP grade quality levels, making it suitable for both laboratory development work and regulated biomanufacturing workflows. Because CRM197 is non-toxic and derived from diphtheria toxin through mutation, it is a preferred choice for applications that require strong immunological performance while maintaining safety and consistency. For B2B buyers, CRM-197 protein is an important raw material for vaccine formulation, conjugation studies, immunogenicity enhancement, and therapeutic research. It is especially relevant to pharmaceutical companies, biotechnology firms, research institutions, and contract development and manufacturing organizations seeking a dependable carrier protein for advanced biologics pipelines. With MOQ 1 from Swasti Exports, this listing supports flexible procurement for R&D and production planning.

*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.